Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

‘Restarting Is Harder Than Stopping’: UK Elective Care Faces Challenges Beyond COVID-19

Executive Summary

Elective surgery is only “elective” in terms of timing, and is not optional. So says British Orthopaedic Association VP-elect John Skinner in the context of how post-COVID-19 planned care will move forward in the UK.

You may also be interested in...



COVID-19: UK NHS Chief Calls For 90% Return To Planned Care Within 3 Months

The much-anticipated return to a “normal” NHS service delivery could yet be dashed by a resurgence of the virus.

UK Medtech Industry Seeking More Clarity On Restart Of Elective Procedures

COVID-19 led to a significant reduction in elective procedures carried out by the UK NHS, broke referral pathways, and put a virtual halt to diagnostics and screening programs. The likely next stages and the concerns of the medtech sector are top priorities for the ABHI.

What Next For Medtech And Investors Post-Coronavirus?

If a post-COVID-19 economic recovery starts properly in September, as some have suggested, how swift would a return to normal be for medtech and life sciences businesses? It depends what the new normal looks like, suggests life sciences legal firm Goodwin. But in the regulatory arena, agencies are working hard to keep market access a priority during the ongoing public health emergency.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT142353

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel